Yiling Pharmaceutical once again responded to doubts, and its market value has evaporated by nearly 7 billion
Yiling Pharmaceuticals responded again to doubts, and its market value has evaporated by nearly 7 billion. According to Wang Sicong’s Weibo, he Forwarded a message about Lianhua Qingwen Capsules, and commented, "The China Securities Regulatory Commission should strictly investigate Yiling Pharmaceutical." Yiling Pharmaceutical responded to the question again, and its market value has evaporated by nearly 7 billion. Yiling Pharmaceutical responded to doubts again, and its market value has evaporated by nearly 7 billion1
A few days ago, Wang Sicong questioned the efficacy of Yiling Pharmaceutical (002603) Lianhua Qingwen on Weibo, which triggered a heated discussion on the Internet. Yesterday, it also As a result, Yiling Pharmaceutical's stock price fell by the limit, and its market value fell from about 67 billion to 60 billion.
Previously, the secretary of the board of directors of Yiling Pharmaceuticals has responded to the doubts, saying, "Regarding the news posted on Weibo, please point out the specific questions and sources, and we will answer the specific content. From the clinical perspective We have complete evidence and report disclosures from the trials to the specific experimental data and inclusion in the COVID-19 diagnosis and treatment plan, including indications and instructions.
We cannot let the word "Wang Sicong" go. Just feel free to ask questions and just listen to some comments on the Internet. Investors should be careful. ”
Now Yiling Pharmaceutical has once again responded to the concerns about Lianhuaqing. Regarding the treatment of COVID-19, the relevant person in charge of Yiling Pharmaceutical stated to "Chinese Entrepreneur": "The company has never stated on any occasion that 'WHO recommends Lianhua Qingwen'."
According to the Securities Times, at 13:08 on April 14, Wang Sicong forwarded a message about Lianhua Qingwen Capsules on Weibo and said that regulatory authorities should strictly investigate Yiling Pharmaceuticals Industry.
About an hour later, Wang Sicong edited the Weibo post again, deleting the words that regulatory authorities should strictly investigate Yiling Pharmaceuticals. Yiling Pharmaceutical once again responded to doubts, and its market value has evaporated by nearly 7 billion 2
The relevant person in charge of Yiling Pharmaceutical stated to "Chinese Entrepreneur": "The company has never stated on any occasion that it is recommended by the WHO. Lianhua Qingwen'". Previously, Wang Sicong shouted to the China Securities Regulatory Commission from a distance, hoping to strictly investigate Yiling Pharmaceutical. On April 14, Yiling Pharmaceutical fell to the limit and finally closed at 35.99 yuan per share. The market value of that day evaporated by 6.7 billion yuan.
On April 14, Wang Sicong showed off his power again. This time, he targeted not entertainment stars, but Yiling Pharmaceutical, the only company in the world that produces Lianhua Qingwen drugs. This company sent hot searches.
According to Wang Sicong’s Weibo, he forwarded a message about Lianhua Qingwen Capsules and commented, “The China Securities Regulatory Commission should strictly investigate Yiling Pharmaceutical.”
About an hour after reposting, Wang Sicong deleted the reposted remarks, but still retained the content about Lianhua Qingwen. In this regard, some media reported that the Securities Department of Yiling Pharmaceutical stated externally, “From clinical trials to specific experimental data, to being included in the new coronavirus pneumonia diagnosis and treatment plan, including indications and instructions, we have complete evidence. and report disclosure. Don’t just raise questions because of the word ‘Wang Sicong’. Just listen to some comments on the Internet. Investors should be careful.”
After the incident, in April. On the 14th, Yiling Pharmaceutical performed very strongly and eventually hit the daily limit. However, on April 15, the incident continued to ferment, and Yiling Pharmaceutical finally fell to the limit, closing at 35.99 yuan/share.
Public information shows that Yiling Pharmaceutical is mainly engaged in the research and development, production and sales of Chinese patent medicines, and its Lianhua Qingwen products have become popular in the fight against the epidemic. Since 2022, its stock price has skyrocketed from 20.35 yuan, reaching a record high of 43.12 yuan on April 12.
Recently, with the outbreak of the epidemic in Shanghai and other places, Lianhua Qingwen has become an epidemic prevention material for many residents.
On March 31, the WHO website released the "Report of the World Health Organization Expert Evaluation Meeting on Traditional Chinese Medicine in Treating COVID-19", which clearly affirmed the safety and effectiveness of traditional Chinese medicine in treating COVID-19 and encouraged the WHO to Member countries of the organization consider the Chinese model of integrating traditional Chinese and Western medicine.
According to the message forwarded by Wang Sicong, he questioned that there was no clear report on the "WHO recommendation of Lianhua Qingwen Capsules".
Up to now, Yiling Pharmaceutical has not issued a clarification announcement regarding the hotly discussed "World Health Organization recommends Lianhua Qingwen" in this incident. In addition to Wang Sicong, other investors questioned Yiling Pharmaceutical's alleged information disclosure violations.
In fact, judging from the performance of Yiling Pharmaceutical, from 2019 to September 2021, Yiling Pharmaceutical’s revenue was 5.825 billion yuan, 8.782 billion yuan and 8.112 billion yuan respectively, and its net profits were respectively They were 607 million yuan, 1.219 billion yuan and 1.224 billion yuan. The epidemic had a significant boost on its performance.
During the same period, Yiling Pharmaceutical’s stock price also rose from a high of 8 yuan/share at the beginning of 2020 to a recent 39.99 yuan/share, an increase of nearly 4 times. However, under Wang Sicong's doubts, the company's stock price has begun to fall. What do you think of Wang Sicong’s doubts? Yiling Pharmaceutical once again responded to the doubts, saying that its market value has evaporated by nearly 7 billion.
Yiling Pharmaceutical stated that it had an academic cooperation with Academician Zhong Nanshan, and Academician Zhong Nanshan did not receive any remuneration for his services, let alone Yiling Pharmaceutical. industry investors.
On April 14, the day after Wang Sicong shouted to the China Securities Regulatory Commission, hoping for a strict investigation of Yiling Pharmaceuticals, Yiling Pharmaceuticals fell to the limit and finally closed at 35.99 yuan per share. The market value of that day evaporated by 67%. billion. On the fourth day, the relevant person in charge of Yiling Pharmaceutical stated to "Chinese Entrepreneur": "The company has never stated on any occasion that 'WHO recommends Lianhua Qingwen'."
The incident originated on April 13, when Wang Sicong, founder of Pulse Capital, forwarded a video on Weibo - "WHO "recommends" Lianhua Qingwen, who told you? ", he wrote in the repost, "The China Securities Regulatory Commission should strictly investigate Yiling Pharmaceutical." As soon as this statement came out, it immediately aroused public opinion. On the afternoon of the 13th, Wang Sicong deleted the comment, leaving only the words "Forward Weibo" and the above video.
In the afternoon of the same day, a staff member of the Securities Department of Yiling Pharmaceutical told the media, "Regarding the news posted on Weibo, please point out the specific problems and sources. It cannot be because of Wang Sicong Just three words, feel free to ask questions."
Why did Wang Sicong propose a strict investigation? What issues do he want to be investigated strictly? It's not clear to the outside world. But judging from the video he forwarded, the target is directly on whether Lianhua Qingwen is a proprietary Chinese medicine recommended by the World Health Organization (WHO) for the treatment of COVID-19.
In this regard, the above-mentioned person in charge explained that the WHO recognized the efficacy of traditional Chinese medicine, including Lianhua Qingwen, in treating COVID-19. The reporter then found a meeting minutes released on March 22 this year on the WHO official website, titled "WHO Expert Assessment Meeting on Traditional Chinese Medicine for the Treatment of COVID-19."
One of the experts quoted a paper on the efficacy and safety of Lianhua Qingwen Capsules in treating COVID-19. The article stated that a multi-center randomized controlled trial was conducted in 9 provinces and 23 hospitals in China. The experiment was carried out between the hospital and 284 patients. The experimental results showed that the new coronavirus patients who took traditional Chinese medicine capsules recovered faster than those who did not take the medicine. The minutes of the meeting also mentioned that experts participating in the meeting recommended that WHO encourage member states to use methods that integrate traditional medicine to treat COVID-19.
However, whether the WHO will use Lianhua Qingwen as a recommended drug for the treatment of COVID-19 was not reflected in the minutes of the meeting. According to the "Report of the World Health Organization Expert Assessment Meeting on Traditional Chinese Medicine for the Treatment of COVID-19", the original words mentioned in it are - WHO member states are encouraged to consider the possibility of using traditional Chinese medicine to treat COVID-19 within their health care systems and regulatory frameworks. .
At the beginning of 2020, the new crown epidemic broke out in Wuhan. In April of that year, the prescription drug Lianhua Qingwen Capsules was approved by the State Food and Drug Administration for the treatment of mild and common COVID-19. As the only company in China that produces Lianhua Qingwen medicine, Yiling Pharmaceutical has gradually become well-known to the Chinese people. The company also has an exclusive patent for the traditional Chinese medicine Lianhua Qingwen.
In early January this year, after the fifth wave of the epidemic broke out in Hong Kong, there was news that Lianhua Qingwen was being used on a large scale. In March this year, after the epidemic broke out in Shanghai, many Shanghai residents who were quarantined at home received distributed Lianhua Qingwen capsules and granules. Lianhua Qingwen became the number one main drug in Shanghai's fight against the epidemic. However, as Lianhua Qingwen "breaks out" and becomes the "miracle drug" to fight the new crown epidemic, the controversy surrounding whether it is really effective is gradually increasing.
Lianhua Qingwen has been recommended by Academician Zhong Nanshan for many times to treat COVID-19 and is claimed to be effective in suppressing COVID-19. The above-mentioned person in charge told reporters that Academician Zhong Nanshan and Yiling Pharmaceutical have an academic cooperative relationship. Academician Zhong Nanshan has not received any remuneration for his services, and he is not an investor in Yiling Pharmaceutical. Many authoritative experts have recognized Lianhua Qingwen's efficacy against the new coronavirus, which is based on a series of basic and clinical research results conducted by Lianhua Qingwen.
Just before Wang Sicong bombarded Yiling Pharmaceuticals, Jack Ma also became the seventh largest shareholder of Yiling Pharmaceuticals.
Yiling Pharmaceutical’s 2020 interim report shows that Jack Ma has entered the company’s top ten shareholders, holding 4.5803 million shares. By the third quarter of 2021, Jack Ma had increased his holdings by 2.7934 million shares in more than a year, bringing his shareholding to 7.3731 million shares, becoming the company's seventh largest shareholder. As the stock price grows, Jack Ma may profit a lot. An investor inquired about this matter on Huayiyi.com, and the company responded on April 7 that it "does not have relevant detailed information about Mr. Jack Ma of Alibaba."
Since the beginning of this year, the domestic COVID-19 epidemic has remained severe. Yiling Pharmaceutical’s stock price has risen from 8 yuan at the beginning of 2020 to 35.99 yuan per share today, an increase of approximately 4 times. As of April 14, Yiling Pharmaceutical's market value reached 66.8 billion yuan, surpassing Tongrentang and Baiyunshan and ranking behind Pien Tze Huang and Yunnan Baiyao.